The Advertising Standards Authority has banned a billboard advert for a £49 facial serum after ruling that claims it could make users appear as much as five years younger were misleading and unsubstantiated. The poster for Eucerin Hyaluron-Filler Epigenetic Serum, which was displayed at Balham tube station in London, stated the product was “clinically proven” based on a study of 160 people. However, the regulator found major issues in the study design, such as the lack of a control group and dependence on subjective self-assessment from participants. The grievance was lodged in November 2025, prompting the ASA enquiry that ultimately judged the advert misleading and banned it from appearing in its current form.
The Restricted Campaign and Its Controversial Claims
The Eucerin marketing campaign relied heavily on a four-week study featuring 160 individuals who were simply asked to self-report how much younger they felt they appeared after using the serum. This research approach prompted immediate concerns for the ASA, which highlighted multiple significant weaknesses in the study design. Particularly important, the study did not include a control group—a essential component in scientific studies that would have allowed researchers to compare results against a reference point. The absence of such comparisons meant there was no way to establish whether any apparent benefits were truly due to the serum or merely the result of placebo response, inherent skin differences, or additional outside influences.
Beiersdorf, the business behind Eucerin, attempted to justify the “up to five years younger” claim by contending it represented a real upper result rather than a standard result. However, the concerns raised by the ASA extended past the main investigation. The watchdog highlighted that the serum had been tested in a different environment to the United Kingdom, prompting concerns about whether results would translate to British consumers. Additionally, three supporting items of evidence provided by Beiersdorf consisted completely of research that had not been published, whilst a fourth—a study that had been peer-reviewed on the active ingredient—did not even assess the serum itself, further eroding the substantiation for the ambitious anti-ageing assertions.
- Study was missing comparative baseline to confirm actual product performance
- Self-reporting by participants created subjective bias into findings
- Testing performed in alternative climate conditions than UK market
- Corroborating data largely unpublished and methodologically questionable
Compliance Issues and Problematic Approach
Why the Research Did Not Meet Benchmarks
The ASA’s investigation uncovered critical shortcomings in how Beiersdorf carried out and disclosed its research. The missing recruitment information meant the watchdog could not verify whether participants were actually indicative of the broader consumer base or if recruitment bias had skewed results towards desirable conclusions. Without knowing how volunteers were recruited, whether they had previous exposure with skincare products, or if they possessed prior loyalty for the brand, the credibility of their responses became severely compromised. These research limitations are the very type that regulatory bodies assess carefully when evaluating claims that could influence purchasing decisions.
Self-reporting by study participants added a significant layer of subjective bias into the findings. Asking individuals to gauge how many years younger they appeared is fundamentally problematic, as perceptions of ageing are deeply personal and influenced by mental processes, lighting conditions, and individual expectations. The ASA rightly questioned whether participants’ responses reflected genuine physical changes or merely their hopes and beliefs about the product’s efficacy. This distinction matters considerably when a company seeks to market a £49 serum as “clinically proven”—a phrase suggesting rigorous, objective scientific validation rather than individual subjective views.
- No comparison cohort meant unable to determine the actual effects
- Selection methodology not revealed, introducing selection bias concerns
- Personal self-reporting cannot serve as clinical proof of efficacy
- Varying environmental conditions compromised applicability to British users
- Supporting evidence largely unpublished, limiting independent scientific scrutiny
Common Challenge with Cosmetics Marketing
The Eucerin serum ban is merely the most recent example of false assertions that has affected the cosmetics advertising industry for years. Beauty companies have consistently stretched the limits of permissible marketing language, utilising aspirational language and pseudo-scientific language to persuade consumers that products provide transformative results. Lianne Sykes, an marketing specialist in aesthetics who consults with firms on responsible marketing conduct, stresses that this problem is systemic rather than isolated. Companies often place emphasis on compelling marketing narratives over rigorous substantiation, relying on the assumption that consumers will not scrutinise claims too closely or that regulatory action will be slow.
The cosmetics industry capitalises on inherent consumer desire for noticeable enhancements in appearance, providing fertile ground for overstated claims. When companies use phrases like “clinically proven” without satisfying the rigorous requirements that such language necessitates, they undermine the trust consumers place in scientific terminology. The ASA’s findings suggest that Beiersdorf’s approach—submitting unpublished research, running studies in unfavourable environments, and relying on subjective self-assessment—exemplifies a concerning but not uncommon strategy. Without sustained oversight and greater transparency from suppliers, consumers stay susceptible to marketing claims that favour revenue over honesty.
What Customers Should Scrutinise
Rather than adopting cosmetic claims uncritically, consumers should establish a more critical approach to evaluating cosmetic advertising. Sykes recommends posing key questions when making purchases, notably when companies put forward assertions about tangible results. Understanding the testing methods used, who participates in studies, and what metrics are actually measured can uncover whether claims rest on solid evidence or advertising hype. Consumers must acknowledge that healthy skin typically results from consistent habits and personal genetics rather than putting faith in a sole miracle product, irrespective of its price point or branding.
- How is skin condition systematically assessed and tracked over time?
- Were trials conducted on varied age ranges and skin types?
- Is the evidence published and independently verifiable by researchers?
- Does the test conditions align with real-world conditions where people reside?
Beiersdorf’s Reaction and Forthcoming Consequences
Beiersdorf, the German multinational corporation that owns the Eucerin brand, has maintained that its products are supported by credible scientific investigation carried out in line with sector guidelines. The company defended its choice to state the claim as “up to” five years younger, contending this phrasing correctly captured the true maximum outcome detected rather than a typical outcome. However, the ASA’s detailed scrutiny of the methodology—including the absence of a control group, lack of transparency about how participants were selected, and dependence on subjective self-assessment—suggests that industry standards alone might not be adequate to safeguard consumers from misleading assertions.
The prohibition indicates a broader shift in regulatory oversight against cosmetics advertising, though uncertainty persists about whether isolated cases translate into systemic change. Beiersdorf confirmed that the billboard advertisement is no longer live in the UK, but the ruling highlights key concerns about how widely comparable assertions persist across other products and marketing channels. If enforcement proceeds at this rate, companies may face mounting pressure to commit resources to truly comprehensive clinical evidence rather than relying on the ambiguity of unsubstantiated findings. For consumers, this case underscores the necessity of requiring openness and questioning even long-standing brands.